share_log

6-K: Lenrep Shows Overall Survival Benefit in Head-to-Head Dreamm-7 Phase Iii Trial for Relapsed/Refractory Multiple Myeloma

6-K: Lenrep Shows Overall Survival Benefit in Head-to-Head Dreamm-7 Phase Iii Trial for Relapsed/Refractory Multiple Myeloma

6-K:Lenrep在針對復發/難治性多發性骨髓瘤的Dreamm-7III期頭對頭試驗中顯示出總體生存獲益
美股SEC公告 ·  11/14 06:46
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息